Royce & Associates’s GeneDx Holdings WGS Stock Holding History

Royce & Associates’s Portfolio WGS Stock Details WGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.7M	Sell	112,136 -28,377	-20%	-$1.61M	0.06%	427
2026 Q1	$9.02M	Buy	140,513 +64,730	+85%	+$5.9M	0.09%	359
2025 Q4	$9.86M	Sell	75,783 -27,416	-27%	-$3.76M	0.1%	308
2025 Q3	$11.1M	Buy	103,199 +9,587	+10%	+$1.04M	0.11%	270
2025 Q2	$8.64M	Buy	93,612 +62,045	+197%	+$4.87M	0.09%	327
2025 Q1	$2.8M	Hold	31,567	–	–	0.03%	543
2024 Q4	$2.43M	Buy	31,567 +3,274	+12%	+$229K	0.02%	602
2024 Q3	$1.2M	Buy	+28,293	New	+$956K	0.01%	704

Other funds holding WGS

Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Royce & Associates's WGS Position: Q2 2026 in Review

Royce & Associates reduced its GeneDx Holdings (WGS) stake by 20% in Q2 2026, selling an estimated $1.61M and leaving 112,136 shares worth $7.7M. The position accounts for 0.06% of the portfolio, ranked #427.

Royce & Associates first reported a position in WGS in Q3 2024 and has held it in 8 quarters since. The position peaked at $11.1M in Q3 2025. 223 funds tracked by Wall St. Rank hold WGS as of Q2 2026.

Royce & Associates held 112,136 shares of GeneDx Holdings worth $7.7M as of Q2 2026.
Royce & Associates sold 28,377 GeneDx Holdings shares in Q2 2026, an estimated $1.61M.
GeneDx Holdings made up 0.06% of Royce & Associates's portfolio in Q2 2026, its #427 holding.
Royce & Associates first reported a position in GeneDx Holdings in Q3 2024 and has held it in 8 quarters since.
Royce & Associates's GeneDx Holdings position peaked at $11.1M in Q3 2025.
223 funds tracked by Wall St. Rank held GeneDx Holdings as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.